Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Danuglipron (PF-06882961) Formulations in Healthy Subjects
NCT03492697Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of danuglipron in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Time to Maximum Observed Plasma Concentration at 48 hours and 6 more. Started Apr 2018; status: completed.
02
Drugs
danuglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT03492697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492697.